Praxis Precision Medicines announced positive topline results from its EMBOLD Phase 2 study evaluating relutrigine in patients with SCN2A and SCN8A developmental and epileptic encephalopathy (DEE). The study showed a significant reduction in seizures, improvements in behavior and communication, and a favorable safety profile.